Recent thiazolidinediones as antidiabetics

Journal of Scientific and Industrial Research

Volumn 66, Issue 2, 2007, Pages 99-109

  Imran, Mohd ^a   Ilyas, Babar ^a   Deepanjali, ^a   Khan, Suroor Ahmad ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Insulin sensitizing agents; Netoglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

DRUG PRODUCTS; DRUG THERAPY; INSULIN; MEDICAL PROBLEMS; TOXICITY;

DIABETES; DRUG DEVELOPMENT; TOXICITY;

EID: 33847102169     PISSN: 00224456     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Reaven G M, Role of insulin resistance in human disease, Diabetes, 37 (1988) 1595-1607.
2. DeFronzo R A, Pharmacologic therapy for type 2 diabetes mellitus, Ann Intern Med, 131 (1999) 281-303.
3. Zimmet P Z, Alberti K G M M & Shaw J, Global and societal implications of the diabetes epidemic, Nature, 414 (2001) 782-787.
4. Mokdad A H, Ford E S, Bowman B A, Dietz W H, Vinicor F, Vales B S & Marks J S, Prevalence of obesity, diabetes and obesity related health factors in 2001, J Am Med Assoc, 289 (2003) 76-79.
5. Ford E S, Giles W H & Dietz W H, Prevalence of metabolic syndrome among US adults, J Am Med Assoc, 287 (2002) 356-359.
6. Diamond J, The double puzzle of diabetes, Nature, 423 (2003) 599-602.
7. American Diabetes Association, Economic cost of diabetes in the U.S. in 2002, Diabetes Care, 26 (2003) 917-932.
8. Porte D Jr, & Schwartz M W, Diabetes complications: Why is glucose potentially toxic?, Science, 27 (1996) 699-700.
9. Skyler J S, Diabetes mellitus: Pathogenesis and treatment strategies, J Med Chent, 47 (2004) 4113-4117.
10. Meriden T, Progress with thiazolidinediones in the management of type 2 diabetes mellitus, Clin Ther, 26 (2004) 177-190.
11. Nathan D M, Initial management of glycemia in type 2 diabetes mellitus, N Engl J Med, 347 (2002) 1343-1349.
12. Inzucchi S E, Oral antihyperglycemic therapy for type 2 diabetes: Scientific review, J Am Med Assoc, 287 (2002) 360-372.
13. DeWitt D E & Hirsch I B, Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review, J Am Med Assoc, 289 (2003) 2254-2264.
14. DeWitt D E & Dugdale D C, Using new insulin strategies in the outpatient treatment of diabetes: Clinical applications, J Am Med Assoc, 289 (2003) 2265-2269.
15. Kazlauskaite R & Fogelfeld L, Insulin therapy in type 2 diabetes, Drug Dis-Mon, 49 (2003) 377-424.
16. Lebovitz H E, Insulin secretogogues: Old and new, Diabetes Rev, 7 (1999) 139-153.
17. Cusi K & DeFronzo R A, Metformin: A review of its metabolic effects, Diabetes Rev, 6 (1998) 89-131.
18. Kirpichnikov D, McFarlane S I & Sowers J R, Metformin: An update, Ann Intern Med, 137 (2002) 25-33.
19. Diamant M & Heine R J, Thiazolidinediones in type 2 diabetes mellitus: Current clinical evidence, Drugs, 63 (2003) 1373-1405.
20. Lebovitz H E, α-Glucosidase inhibitors as agent in the treatment of diabetes, Diabetes Rev, 6 (1999) 132-145.
21. Seltzer H S, Drug-induced hypoglycemia. A review of 1418 cases, Endocrinol Metab Clin North Am, 18 (1989) 163-183.
22. O'Moore-Sullivam T M & Prins J B, Thiazolidinediones and type 2 diabetes: New drug for an old disease, Med J Aust, 176 (2002) 381-396.
23. Lehman J M, Moore L B, Smith-Oliver T A, Wilkison W O, Willson T M & Kliewer S A, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ), Biol Chem, 270 (1995) 12953-12956.
24. Saltiel A R & Olefsky J M, Thiazolidinediones in the treatment of insulin resistance and type II diabetes, Diabetes, 45 (1996) 1661-1669.
25. 2 in adipose tissue of high fat fed rats, Biochem Biophys Res Commun, 229 (1996) 752-757.
26. Ferrarl C, Testorl G P, Betazzonl A, Rommussl M, Caldara R & Frezzati S, Increased glucose disappearance rate after short term clofibrate administration in normal subjects and in patients with chemical diabetes, Horm Metab Res, 10 (1978) 4-6.
27. Barnett K, Craig J G, Robinson D S & Rogers M, Effect of clofibrate on glucose tolerance in maturity onset diabetes, Br J Clin Pharmacol 4 (1977) 455-458.
28. Sodha T, Mizuno K, Imamiya E, Sugiyama Y, Fujita T & Kawamatsu Y, Studies on antidiabetic agents II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidinedione (ADD-3878) and its derivatives, Chem Pharm Bull, 30 (1982) 3580-3600.
29. Fujita T, Sugiyama Y, Taketomi S, Sodha T, Kawamatsu Y, Iwatsuka H & Suzuoki Z, Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidinedione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent, Diabetes, 32 (1983) 804-810.
30. Chang A Y, Wyse B M, Gilchrist B J, Peterson T & Diani A R, Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats, Diabetes, 32 (1993) 830-838.
31. Yoshloka T, Fujita T, Kanai T, Alzawa Y, Kurumada T, Hasegawa K & Horikoshi H, Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation, J Med Chem, 32 (1989) 421-428.
32. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I & Horikoshi H, Characterization of new oral antidiabetic agent, CS-045. Studies in KK and ob/ob mice and Zucker fatty rats, Diabetes, 37 (1998) 1549-1558.
33. Suter S L, Nolan J J, Wallace P, Gumbine J M & Olefsky J M, Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects, Diabetes Care, 15 (1992) 193-203.
34. Clark D A, Goldstein S W, Volkmann R A, Eggler J F, Holland G F, Hulin B, Stevenson R W, Kreutter D K, Gibbs E M, Krupp M N & Merrigan P, Substituted dihydro-benzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents, J Med Chem, 34 (1991) 319-325.
35. Momose Y, Meguso K, Ikeda H, Hatanaka C, Oi S & Sodha T, Studies on antidiabetic agent X: Synthesis and biological activities, Chem Pharm Bull, 39 (1991) 1440-1445.
36. Cantello B C C, Cawthorne M A, Haigh D, Hindley R M, Smith S A & Thurlby P L, The synthesis of BRL-49653- A novel and potent antihyperglycemic agent, Biomed Chem Lett, 4 (1994) 1181-1184.
37. Momura M, Kinoshita S, Satoh H, Maeda T, Murakami K, Tsunoda M, Miyachi H & Awano K, (3-Substituted benzyl) thiazolidine-2,4-diones as structurally new antihyperglycemic agents, Bioorg Med Chem Lett, 9 (1999) 533-538.
38. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi O, Akanuma Y, Yazaki Y & Kadowaki T, A novel insulin sensitizer acts as a coligand for proliferators peroxisome-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats, Diabetes, 47 (1998) 1841-1847.
39. Sorbera L A, Castaner J, Fresno M D & Silvestre J, Netoglitazone. Antidiabetic PPARγ/PPARα agonist, Drugs of Future, 27 (2002) 132-139.
40. Reddy A K A, Lohray B B, Bhushan V, Reddy A S, Mamidi N V S R, Reddy P P, Saibaba V, Deddy N J, Suryaprakash A, Parimal M, Vikramadithyan R K & Rajagopalan R, Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives, J Med Chem, 42 (1999) 3265-3278.
41. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengorich F P & Yokoi T, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes, Drug Metab Dispos, 27 (1999) 1260-1266.
42. Kawai K, Kawasaki-Toku Y, Odaku T, Tsuruta F, Kazui M, Iwabuchi H, Nakamina T, Kinoshita T, Ikeda T, Yoshioka T, Komai T & Nakamuri T, Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs, Arzneim-Forsch, 47 (1997) 356-368.
43. Fujiwara T & Horikoshi H, Troglitazone and related compounds: Therapeutic potential beyond diabetes, Life Sci, 67 (2000) 2405-2416.
44. Ertan R and Bozdag O, Oral antidiabetic 2,4-thiazolidinedione derivative agents II, FABAD Farm Bilimler Derg, 25 (2000) 57-66
45. Chem Abstr, 134 (2001) 94953.
46. Ghosh N N, Gupta D, Chaudhary J, Chand S, Dass S K & Chandra R, Advances in the chemistry of thiazolidinediones as antidiabetic agents, J Indian Chem Soc, 80 (2003) 1045-1055.
47. Scheen A J, Paquot N, Letiexhe M R & Lefebvre P J, Thiazolidinediones, J Ann Diabetol Hotel-Dieu, (1999) 213-229
48. Chem Abstr, 132 (2000) 231277.
49. Nomura Y, Sakuma S & Masui S, Preparation of (quinolinylalkyl)azolidinedione derivatives for lowering blood sugar, PCT Int Appl WO 96,12,719, 2 May 1996
50. Chem Abstr, 125 (1996) 114599.
51. Yanagisawa H, Fujita T, Fujimoto K, Yoshioka T, Wada K, Oguchi M, Fujiwara T & Horikoshi H, Oxime-containing thiazolidinedione derivatives & analogs, their preparation, and their therapeutic use against diabetes and related conditions, European Pat 708,098, 24 Apr 1996
52. Chem Abstr, 125 (1996) 58495.
53. Nagao Y, Ito Y, Kotake J, Kouda T, Honda H, Sato S & Matsuda H, Preparation of benzoazines for reducing blood glucose level, European Pat 787,727, 6 Aug 1997
54. Chem Abstr, 127 (1997) 205585.
55. Ogawa M, Morita T, Iibuchi N & Tsutsui H, Preparation of thiazolidinediones for treating diabetes mellitus, European Pat 780,389,25 Jun 1997
56. Chem Abstr, 127 (1997) 135790.
57. Prabhakar C, Madhusudhan G, Sahadev K, Reddy C M, Sharma M R, Reddy G O, Chakrabarti R, Rao C S, Kumar T D & Rajagopalan R, Synthesis and biological activity of novel thiazolidinediones, Bioorg Med Chem Lett, 8 (1998) 2725-2730.
58. Wrobel J, Li Z, Dietrich A, McCaleb M, Mihan B, Sredy J & Sullivan S, Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as antihyperglycemic agents, J Med Chem, 41 (1998) 1084-109
59. Lohray B B, Bhushan V, Rao B P, Madhavan G R, Murali N, Rao K N, Reddy A K, Rajesh B M, Reddy P G, Chakrabarti R, Vikramadithyan B K, Rajagopalan R, Mamidi R N V S, Jajoo H K & Subramaniam S, Novel euglycemic and hypolipidemic agents. 1, J Med Chem, 41 (1998) 1619-1630.
60. Lohray B B & Bhushan V, Indole containing thiazolidine-2,4-diones as novel euglycemic and hypolipidemic agents: DRF-2189, Drugs of Future, 24 (1999) 751-757.
61. Chakrabarti R, Vikramadithyan R K, Tripuraneni D K, Kumar K B S, Kumar M P, Mamnoor P, Misra P, Rao P B, Lohray V B, Lohray B B & Rajagopalan R, Studies on euglycemic and hypolipidemic potentials of the novel indole analogue of thiazolidinedione, DRF 2189, Arzneim.-Forsch, 49 (1999) 905-911
62. Chakrabarti R, Vikramadithyan R K, Tripuraneni D K, Kumar K B S, Kumar M P, Mamnoor P, Misra P, Rao P B, Lohray V B, Lohray B B & Rajagopalan R, Chem Abstr, 132 (2000) 88016.
63. Lohray B B, Bhushan V, Reddy A S, Rao P B, Reddy N J, Harikishore P, Haritha N, Vikramadityan R K, Chakrabarti R, Rajagopalan R & Katneni K, Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl containing thiazolidinediones, J Med Chem, 42 (1999) 2569-2581.
64. Reddy K A, Lohray B B, Bhushan V, Reddy A S, Mamidi N V S R, Reddy P P, Saibaba V, Reddy N J, Suryaprakash A, Misra P, Vikramadithyan R K & Rajagopalan R, Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives, J Med Chem, 42 (1999) 3265-3278.
65. Yanagisawa H, Takamura M, Yamada E, Fujita S, Fujiwara T, Yachi M, Isobe A & Hagisava Y, Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: Synthesis and structure-activity relationship, Bioorg Med Chem Lett, 10 (2000) 373-375.
66. Kitajima H, Nakamura M, Tamakawa H & Goto N, Hybridisation of non-sulfonylurea insulin secretagogue and thiazolidinedione-derived insulin sensitizer, Bioorg Med Chem Lett, 10 (2000) 2453-2456.
67. Oguchi M, Wada K, Honma H, Tanaka A, Kaneko T, Sakakibara S, Ohsumi Y, Serizawa N, Fujiwara T, Horikoshi H & Fujita T, Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones, J Med Chem, 43 (2000) 3052-3066.
68. Madhavan G R, Chakrabarti R, Kumar S K B, Misra P, Mamidi R N V S, Balraju V, Kasiram K, Babu R K, Suresh J, Lohray B B, Lohray V B, Iqbal J & Rajagopalan R, Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents, Eur J Med Chem, 36 (2001) 627-637.
69. Fujimori S, Murakami K & Tsunoda M, Preparation of substituted benzylthiazolidine-2,4-dione derivatives as ligands of human peroxisome proliferator-activated receptor, PCT Int Appl WO 01 14,350, 1 Mar 2001
70. Chem Abstr, 134 (2001) 178551.
71. Lohray V B, Lohray B B, Paraselli R B, Rajagopalan R & Chakrabarti R, Preparation of substituted thiazolidinediones having antidiabetic, hypolipidemic and antihypertensive properties, US Pat 6,313,113, 6 Nov 2001
72. Chem Abstr, 135 (2001) 344476.
73. Sahoo S P, Santini C, Boueres J K, Heck J V, Metzger E & Lombardo V K, Preparation of 5-(halo or alkyl)-5-aryl-2,4-thiazolidinedione and oxazolidinedione derivatives as PPAR agonists, PCT Int Appl WO 00 78,312, 28 Dec 2000
74. Chem Abstr, 134 (2001) 71589.
75. Pfahl M, Tachdjian C, Al-Shamma H A, Fanju A, Pleynet D P N & Spran L W, Preparation of benzylidene-thiazolidinediones and analogs as antidiabetics, PCT Int Appl WO 00 16,122, 8 Mar 2001
76. Chem Abstr, 134 (2001) 222707.
77. Madhavan G R, Chakrabarti R. Vikramadithyan R K, Mamidi R N V S. Balraju V, Rajesh B M, Misra P, Kumar S K B, Lohray B B, Lohray V B & Rajagopalan R, Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives, Bioorg Med Chem, 10 (2002) 2671-2680.
78. Momose Y, Maekawa T, Yamano T, Kawada M, Odaka H, Ikeda H & Sodha T, Novel 5-substituted-2,4-thiazolidinedione and oxazolidinedione derivatives as insulin sensitizers with antidiabetic activity, J Med Chem, 45 (2002) 1518-1534.
79. Nag B, Dey D & Medicheria S, Preparation and activity of diphenylethylene thiazolidinediones and analogs as antidiabetics, antiinflammatories, or immunomodulators, US Pat 25,975, 28 Feb 2002
80. Chem Abstr, 136 (2002) 216745.
81. Onota M & Iwai Y, Preparation of benzoic acids and thiazolidinediones for N-benzyldioxothiazolidinylbenzamides as antidiabetic agents, Japanese Pat 354,664, 25 Dec 2001
82. Chem Abstr, 136 (2002) 37600.
83. Pershadsingh H A & Avery M A, Preparation of dithiolanyl thiazolidinediones as peroxisome proliferator-activated receptor γ activators, US Pat 6,353,011, 5 Mar 2002
84. Chem Abstr, 136 (2002) 216739.
85. Storr T, Mitchell D, Buglyo P, Thompson K H, Yuen V G, McNeill J H & Orgvig C, Vanadyl-thiazolidinedione combination agents for diabetes therapy, Bioconj Chem, 14 (2003) 212-221.
86. Tuncbilek M, Bozdag O, Ayhan-Kileigil G, Ceylan M, Waheed A, Verspohl E J & Ertan R, Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives- fifth communication: flavonyl benzyl substituted 2,4-thiazolidinediones, Farmaco, 58 (2003) 79-93.
87. Bozdag O, Verspohl E J & Ertan R, Synthesis and hypoglycemic activity of some new flavone derivatives. Second communication: 4′-flavonyl-2,4-thiazolidinedines, Arzneim-Forsch/Drug Res, 50 (2000) 539-543.
88. Bozdag O, Verspohl E J & Ertan R, Synthesis and hypoglycaemic activity of some new flavone derivatives. Third communication: 3′-flavonyl-2,4-thiazolidinedines, Arzneim-Forsch/Drug Res, 50 (2000) 626-630.
89. Neogi P, Lakner F J, Medicherla S, Cheng J, Dey D, Gowri M, Nag B, Sharma S D, Pickford L B & Gross C, Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents, Bioorg Med Chem, 11 (2003) 4059-4067.
90. Kim B Y, Ahn J B, Lee H W, Moon K S, Sim T B, Shin J S, Ahn S K & Hong C I, Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives, Chem Pharm Bull, 51 (2003) 276-285.
91. Bernardon J M, Clary L & Terranova E, Preparation of 1,1-biphenyl derivatives as biaromatic ligand activators of peroxisome proliferator-activated receptor subtype gamma (PPAR gamma receptor), US Pat 134885, 17 Jul 2003
92. Chem Abstr, 139 (2003) 101121.
93. Bernardon J M & Clary L, Preparation of 4-(2,4-dioxothiazolidin-5-ylmethyl)biphenyl derivatives as new ligand activators' of PPARγ receptor for use in human medicine and in cosmetics, French Pat 2833949, 27 Jun 2003
94. Chem Abstr, 139 (2003) 69254.
95. Druzgala P, Milner P G & Pfister J R, Preparation of benzylazolidinediones for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis, US Pat 3027798, 06 Feb 2003
96. Chem Abstr, 138 (2003) 153526.
97. Kim B Y, Ahn J B, Lee H W, Kang S K, Lee J H, Shin J S, Ahn S K, Hong C I & Yoon S S, Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiaziolidinedione, Eur J Med Chem, 39 (2004) 433-447.
98. Bhat B A, Ponnala S, Sahu D P, Tiwari P, Tripathi B K & Srivastava A K, Synthesis and antihyperglycemic activity profile of novel thiazolidinedione derivatives, Bioorg Med Chem, 12 (2004) 5857-5864.
99. Ramachandran U, Mital A, Bharatam P V, Khanna S, Rao P M, Srinivasan K, Kumar R, Chawla H P S, Lal C K, Raichur S & Chakrabarti R, Studies on some glitazones having pyridine as the linker unit, Bioorg Med Chem, 12 (2004) 655-662.
100. Jeon R & Park S, Synthesis and biological activity of benzoxazole containing thiazolidinedione derivatives, Arch Pharm Res, 27 (2004) 1099-1105.
101. Sattigeri J A & Salman M, Preparation of phenyl acetylene derivatives as agonists of PPAR receptors, PCT Int Appl WO 058813, 30 June 2005
102. Chem Abstr, 143 (2005) 97157.
103. Lu X, Preparation of thiazolidine diketone derivatives as selective RXR/PPARγ modulators, Chinese Pat 1524854, 01 Sep 2004
104. Chem Abstr, 143 (2005) 229831.
105. Gupta D, Ghosh N N & Chandra R, Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6,7-dimethyl-1,2,3,4-tetrahydro-2-oxo-4-quinoxalinyl)ethoxy] phenyl ]methylene]thiazolidine-2,4-dione derivatives as potent euglycemic and hypolipidemic agents, Bioorg Med Chem Lett, 15 (2005) 1019-1022.
106. Pattan S R, Suresh C, Pujar V D, Reddy V V K, Rasal V P & Koti B C, Synthesis and antidiabetic activity of 2-amino[5-4-sulfonylbenzylidene)-2,4-thiazolidinedione]-7-chloro-6- fluorobenzothiazole, Indian J Chem, 44B (2005) 2404-2408.
107. Lee H W, Kim B Y, Ahn J B, Kang S K, Lee J H, Shin J S, Ahn S K, Lee S J & Yoon S S, Molecular design, synthesis and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione, Eur J Med Chem, 40 (2005) 862-874.
108. Mourao R H, Silva T G, Soares A L M, Vieira E S, Santos J N, Lima M C A, Lima V L M, Galdino S L, Barbe J & Pitta I R, Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones, Eur J Med Chem, 40 (2005) 1129-1133.
109. Madhavan G R, Chakrabarti R, Reddy K A, Rajesh B M, Balraju V, Rao P B, Rajagopalan R & Iqbal J, Dual PPAR-α and -γ activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential, Bioorg Med Chem, 14 (2005) 584-591.